Study Published in Advances In Wound Care Shows Venus Leg Ulcers Treated With Spiracur’s Mechanically Powered Negative Pressure Wound Therapy System Superior To Electrically Powered System

SUNNYVALE, CA--(Marketwired - October 22, 2014) - Spiracur announced today that favorable data from a multicenter randomized controlled trial (RCT) comparing negative pressure wound therapy (NPWT) of venous leg ulcers (VLU) using the mechanically powered (MP) SNaP® Wound Care System to the electrically powered (EP) VAC® system, was published in Advances in Wound Care.

The 13-center prospective RCT was performed under the guidance of William A. Marston, M.D., David G. Armstrong, DPM, M.D., Ph.D., Alexander M. Reyzelman, DPM, and Robert S. Kirsner, M.D., Ph.D. Each subject was randomly assigned to treatment with either MP NPWT or EP NPWT and evaluated for 16 weeks or complete wound closure.

According to Dr. Marston, chief, Division of Vascular Surgery at the University of North Carolina School of Medicine, and lead investigator, “VLUs represent a significant challenge for wound care professionals due to their delayed healing and poor wound bed characteristics. NPWT has been effective in improving healing of VLUs, however, traditional EP NPWT has been challenging to implement in outpatient care settings. This study provides insight into the newer MP NPWT modality, the SNaP System, which allows for the practical treatment of these wounds in the outpatient setting.

“The data shows that wounds treated with NPWT combined with compression therapy resulted in healing of refractory chronic VLUs,” continued Dr. Marston. “In addition, an unexpected finding was that, in the patient cohort studied, the SNaP device demonstrated greater improvement and a higher likelihood of complete wound closure than those treated with EP NPWT. Further study of these NPWT devices in larger patient populations is required to confirm these interesting findings.”

Forty patients (19 MP NPWT and 21 EP NPWT) completed the study with either healing or 16 weeks of therapy. Overall, 52.5 percent of VLUs healed at 16 weeks and the average wound achieved 50 percent closure at 5.9 weeks of treatment. At 30 days, 50 percent wound closure was achieved in 52.6 percent of patients treated with the SNaP System and 23.8 percent of patients treated with the V.A.C. system. At 90 days, complete wound closure was achieved in 57.9 percent of patients treated with the SNaP System and 38.15 percent of patients treated with the V.A.C. system.

“Data shows that wounds treated with the SNaP System were twice as likely to achieve 50 percent closure at 30 days compared to those treated with the VAC system,” said Kenton Fong, M.D., chief scientific officer for Spiracur. “These results clearly substantiate the feasibility of the SNaP System as the proven alternative method, and a smart choice for clinicians seeking the best outcomes for VLU treatment.”

About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company’s ciSNaP® Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have received 510(k) clearance from the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. Spiracur’s proprietary mechanically powered technology does not require batteries or electricity to operate. For more information, please visit http://spiracur.com.

Spiracur, Spiracur logo, SNaP, and ciSNaP are registered trademarks of Spiracur Inc.